 |
|
Thrombocytopenia Due to Stibophen
HYMAN R. KAHN, M.D.;
ROBERT C. BROD, M.D.
Arch Intern Med. 1961;108(3):496-501.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Stibophen (Fuadin),* an organic trivalent antimony compound, has been used for many years in the treatment of schistosomiasis. Many side-effects have been reported, but their occurrence has been infrequent. The more common side-effects have been nausea, anorexia, vomiting, dizziness, joint pains, electrocardiographic changes, eosinophilia, and mild upper abdominal pain. The less frequent side-effects have been fever, maculopapular rash, bradycardia, hypotension, hepatic and renal insufficiency, bone marrow depression, retinitis, and neuritis.1-4
That stibophen may induce thrombocytopenic purpura has been suggested by 4 case reports.1,5,6 In 3 of these cases, stibophen was suspected because it was being used at the time that thrombocytopenia occurred, but the conclusion was not substantiated by either a challenge dose or in vitro studies. The fourth case5 is the only reported instance noted in which stibophen was demonstrated to be the etiologic agent. Thrombocytopenic purpura was produced in a normal person by administering stibophen
. . . [Full Text PDF of this Article]
Author Affiliations
PHILADELPHIA
From the Department of Medicine, Division of Cardiology, The Jefferson Medical College.; Southeastern Pennsylvania Heart Association Fellow in Cardiology (Dr. Kahn). Resident in Internal Medicine, U.S. Naval Hospital; formerly Resident in Hematology, Cardeza Foundation, Department of Medicine, The Jefferson Medical College (Dr. Brod).
Footnotes
Submitted for publication July 20, 1960.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
